# US 12,180,157 B2 · Crystalline bufotenidine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,157 B2
- Document ID: US12180157B2
- Status: Granted
- Kind: B2
- Application number: 18/261,395
- Filed: 2022-01-13
- Published: 2024-02-08
- Granted: 2024-12-31
- Earliest claimed: 2021-01-14
- Assignees: Caamtech, Inc.
- Applicants: Caamtech, Inc.
- Inventors: Andrew R Chadeayne
- Web page: https://patentgrep.com/patent/US12180157B2

## CPC

- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 209/16: Tryptamines
- C12P 17/10: Nitrogen as only ring hetero atom
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The disclosure relates to crystalline form 1 of 5-hydroxy-N,N,N-trimethyl-tryptammonium (5-HTQ) iodide, and to pharmaceutical compositions containing the compound and to methods of treatment using it.

## Claims

### Claim 1

Crystalline form 1 of 5-hydroxy-N,N,N-trimethyl-tryptammonium (5-HTQ) iodide characterized by at least one of:
an orthorhombic, P212121 crystal system space group at a temperature of about 297 K;
unit cell dimensions a=8.9944 (4) Å, b=11.3250 (6) Å, and c=14.4042 (7) Å;
an X-ray powder diffraction pattern characterized by at least two peaks selected from 14.0, 16.8, and 17.6°2θ±0.2°2θ; or
an X-ray powder diffraction pattern substantially similar to FIG. 3.

### Claim 2 (depends on 1)

A composition comprising crystalline form 1 of 5-HTQ iodide according to claim 1 and an excipient.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of crystalline form 1 of 5-HTQ iodide according to claim 1 and a pharmaceutically acceptable excipient.

### Claim 4 (depends on 1)

A composition comprising crystalline form 1 of 5-HTQ iodide according to claim 1 and a second component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, or (i) a purified hericenone.